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  Prophylactic effects ef combined intravesical instillation of cytosine arabinoside and carboquone
on recurrence rate of bladder tumor were studied in 42 patients． Thirty ml solution containing cytosine
arabinoside 100 mg and carboquone 10 mg was instiiled into the bladder once a week for IO weeks，
and once a month f6r subsequent 10 rnonths．
  The recurrence rate was 14．60／． after 1 year， 27．40／， after 2 year， 33．402． after 3 year， 33．40／a after
4 and 5 years follow up．
  On the basis of our observation， it is concluded that the prophylactic instillation therapy with
cytosine arabinoside and carboquone is effective for the prevention of postoperative recurrence of
bladder tumors．













    2） 対象症例および注入方法
 対象は1975年より1979年までの4年間に徳島大学泌
尿器科および徳島県立中央病院にて治療をうけた膀胱
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Fig． 1． Bladder instillation schedule




























Table 2． Recurrence rate of bladder tumor after intravesical instillation （Actuarial method）
Fttow－up yr． of observation O一 lyr 1 一一 2yr 2一 3yr 3一 4yr 4一 5yr 5一 6yr
No． not recurrent at beginning of yr・〔lx，
No． recurrent during yr． 〔dx⊃
．No・last seen not recurrent during yr。〔Wx⊃
                    グEffective no。 exposed to risk of recurrence 〔1x｝
Proportion recurrent during yr． ｛qx〕
Proportion not recurrent during yr．〔px〕
proportion not recurrent from treatment to end of yr． （Px｝
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